Gene:
P2RY1
purinergic receptor P2Y, G-protein coupled, 1

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132) 		Alternate Names ? Drugs ? Alleles ?
(+ chr strand) 		Function ? Amino Acid?
Translation
rs1065776 P2RY1:893C>T, P2RY1:C893T, c.57C>T, g.59048774C>T
C > T
 Not Available
Ala19Ala
VIP No Clinical Annotations available No Variant Annotations available
rs701265 P2RY1:1622A>G, P2RY1:1622AG, P2RY1:A1622G, c.786A>G, g.59049503A>G
A > G
 Not Available
Val262Val
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  ATP receptor; P2 purinoceptor subtype Y1; P2Y purinoceptor 1; platelet ADP receptor; purinergic receptor P2Y1
Alternate Symbols:  P2Y1
PharmGKB Accession Id: PA32868

Details

Cytogenetic Location: chr3 : q25.2 - q25.2
GP mRNA Boundary†: chr3 : 152552736 - 152555845
GP Gene Boundary†: chr3 : 152542736 - 152558845
Strand: plus
Product Name: No data available
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNA11
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNA12
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNA13
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNA15
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAI3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNAQ
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GNB3

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
aspirin
No related diseases are available

Publications related to P2RY1: 9

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
Platelet aggregation pathway. Pharmacogenetics and genomics. 2010. Sangkuhl Katrin, et al. [Article:20938371@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. [Article:21142917@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of platelet reactivity in normal, healthy individuals. Journal of thrombosis and haemostasis : JTH. 2009. Kunicki T J, et al. [Article:19740098@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007. Li Qing, et al. [Article:17559347@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thrombosis research. 2007. Lev Eli I, et al. [Article:16581111@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. Journal of thrombosis and haemostasis : JTH. 2006. Sibbing D, et al. [Article:16634769@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacology & therapeutics. 2005. Gachet Christian. [Article:15955565@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Aspirin resistance and a single gene. The American journal of cardiology. 2005. Jefferson Brian K, et al. [Article:15757620@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. The Journal of clinical investigation. 1999. Léon C, et al. [Article:10606627@PubMed]

LinkOuts

Entrez Gene:
5028
OMIM:
601167
UCSC Genome Browser:
NM_002563
RefSeq RNA:
NM_002563
RefSeq Protein:
NP_002554
RefSeq DNA:
AC_000046
AC_000135
NC_000003
NT_005612
NW_001838884
NW_921807
UniProtKB:
P2RY1_HUMAN (P47900)
Ensembl:
ENSG00000169860
GenAtlas:
P2RY1
GeneCard:
GC03P152552 (5028)
MutDB:
P2RY1
ALFRED:
LO289470E
HuGE:
P2RY1
Comparative Toxicogenomics Database:
5028
ModBase:
P47900
HumanCyc Gene:
HS10020
IUPHAR Receptor:
P2Y1 (323)
HGNC:
8539

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.